Major Depressive illness
MHRA Drug Safety Update - Citalopram and escitalopram: QT interval prolongation
Central nervous system
Use should be reserved for patients with major depressive illness only. (As per product license)
The colour classification was determined as part of the collaborative work between LCFT and medicines Management leads. Local pathways and patient safety were taken into consideration.
Reason for decision:
Suitable for initiation in primary care in line with restrictions